| Pathophysiology and management of monoclonal gammopathy of renal significance A Jain, R Haynes, J Kothari, A Khera, M Soares, K Ramasamy Blood advances 3 (15), 2409-2423, 2019 | 78 | 2019 |
| Long term outcomes in monoclonal gammopathy of renal significance A Khera, F Panitsas, F Djebbari, K Kimberger, S Stern, J Quinn, N Rabin, ... British Journal of Haematology 186 (5), 706-716, 2019 | 32 | 2019 |
| Myeloma Genome Project Panel is a comprehensive targeted genomics panel for molecular profiling of patients with multiple myeloma P Sudha, A Ahsan, C Ashby, T Kausar, A Khera, MH Kazeroun, CC Hsu, ... Clinical Cancer Research 28 (13), 2854-2864, 2022 | 14 | 2022 |
| Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care F Djebbari, F Panitsas, TA Eyre, C Prodger, F Davies, K Burton, A Khera, ... haematologica 105 (9), e474, 2020 | 14 | 2020 |
| Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort … F Djebbari, A Rampotas, F Panitsas, WY Lim, C Lees, I Tsagkaraki, ... Plos one 17 (1), e0262388, 2022 | 6 | 2022 |
| Efficacy and tolerability of VCD chemotherapy in a UK real‐world dataset of elderly transplant‐ineligible newly diagnosed myeloma patients A Rampotas, F Djebbari, F Panitsas, C Lees, I Tsagkaraki, AR Gomes, ... European Journal of Haematology 106 (4), 563-573, 2021 | 2 | 2021 |
| Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experience F Djebbari, H Hubenov, P Neelakantan, J Wolf, M Offer, A Khera, E Louka, ... British journal of haematology 188 (4), e57-e60, 2020 | 2 | 2020 |
| P-322 Real world outcomes of belantamab mafodotin from the UK and Ireland: updated results E Watson, F Djebbari, F Panitsas, G Vallance, S Asher, M Saeed, ... Clinical Lymphoma, Myeloma and Leukemia 23, S215-S216, 2023 | | 2023 |
